Interestingly, a subsequent pathology study by Ararnio et al. (2012) found that renal cancer amongst MLH1 mutation carriers was low (1.3%), and that MSI was infrequent despite deficient MMR upon immunohistochemistry analysis, suggesting that renal cancer may not be related to the LS tumour spectrum [32]. Here, MLH1 is linked to neoplasm.